Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review
<p></p><div> <p>Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR–ABL<sup>+</sup> B-ALL. Dasatinib is a potent second-generation TKI. Here, we have discussed the case of a 51-year-old gentleman diagnosed with B-myeloid mixed-phenotype a...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513565248978944 |
|---|---|
| author | Theresa Paul (13140759) |
| author2 | Anil Yousaf Ellahie (8984072) Yazan Salah Almohtasib (14778784) Urshita Sinha (14778787) Halima El Omri (14778790) |
| author2_role | author author author author |
| author_facet | Theresa Paul (13140759) Anil Yousaf Ellahie (8984072) Yazan Salah Almohtasib (14778784) Urshita Sinha (14778787) Halima El Omri (14778790) |
| author_role | author |
| dc.creator.none.fl_str_mv | Theresa Paul (13140759) Anil Yousaf Ellahie (8984072) Yazan Salah Almohtasib (14778784) Urshita Sinha (14778787) Halima El Omri (14778790) |
| dc.date.none.fl_str_mv | 2023-03-16T06:23:42Z |
| dc.identifier.none.fl_str_mv | 10.1002/jha2.226 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Dasatinib_induced_chylothorax_An_unusual_presentation_of_a_common_adverse_event_A_case_report_with_literature_review/22258225 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Chylothorax Dasatinib glucose–lipidmetabolism imatinib leukemia pleuraleffusion yrosine kinase inhibitors |
| dc.title.none.fl_str_mv | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p></p><div> <p>Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR–ABL<sup>+</sup> B-ALL. Dasatinib is a potent second-generation TKI. Here, we have discussed the case of a 51-year-old gentleman diagnosed with B-myeloid mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR–ABL1p210, in complete hematological, cytogenetic, and molecular remission, who developed chylothorax. Though pleural effusion is a commonly observed adverse effect of dasatinib therapy, chylothorax is rare. The ability of Dasatinib to inhibit multiple families of tyrosine kinases could be considered the etiology. Discontinuation of the drug resolved the symptom, but pleural effusion recurred once Dasatinib was resumed. Chylothorax induced by Dasatinib is a differential to be kept in mind, owing to the limited number of cases being reported.</p> </div><p></p><h2>Other Information</h2> <p> Published in: eJHaem<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/jha2.226" target="_blank">http://dx.doi.org/10.1002/jha2.226</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_723cf4f7926ff645fa1aa81205027d34 |
| identifier_str_mv | 10.1002/jha2.226 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22258225 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature reviewTheresa Paul (13140759)Anil Yousaf Ellahie (8984072)Yazan Salah Almohtasib (14778784)Urshita Sinha (14778787)Halima El Omri (14778790)Biomedical and clinical sciencesCardiovascular medicine and haematologyChylothoraxDasatinibglucose–lipidmetabolismimatinibleukemiapleuraleffusionyrosine kinase inhibitors<p></p><div> <p>Tyrosine kinase inhibitors (TKIs) are the key agents for treating CML and BCR–ABL<sup>+</sup> B-ALL. Dasatinib is a potent second-generation TKI. Here, we have discussed the case of a 51-year-old gentleman diagnosed with B-myeloid mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR–ABL1p210, in complete hematological, cytogenetic, and molecular remission, who developed chylothorax. Though pleural effusion is a commonly observed adverse effect of dasatinib therapy, chylothorax is rare. The ability of Dasatinib to inhibit multiple families of tyrosine kinases could be considered the etiology. Discontinuation of the drug resolved the symptom, but pleural effusion recurred once Dasatinib was resumed. Chylothorax induced by Dasatinib is a differential to be kept in mind, owing to the limited number of cases being reported.</p> </div><p></p><h2>Other Information</h2> <p> Published in: eJHaem<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1002/jha2.226" target="_blank">http://dx.doi.org/10.1002/jha2.226</a></p>2023-03-16T06:23:42ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/jha2.226https://figshare.com/articles/journal_contribution/Dasatinib_induced_chylothorax_An_unusual_presentation_of_a_common_adverse_event_A_case_report_with_literature_review/22258225CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222582252023-03-16T06:23:42Z |
| spellingShingle | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review Theresa Paul (13140759) Biomedical and clinical sciences Cardiovascular medicine and haematology Chylothorax Dasatinib glucose–lipidmetabolism imatinib leukemia pleuraleffusion yrosine kinase inhibitors |
| status_str | publishedVersion |
| title | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review |
| title_full | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review |
| title_fullStr | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review |
| title_full_unstemmed | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review |
| title_short | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review |
| title_sort | Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Chylothorax Dasatinib glucose–lipidmetabolism imatinib leukemia pleuraleffusion yrosine kinase inhibitors |